Tranzyme Partners with Bristol-Myers, Lilly Fights Patent Cliff: Healthcare Business Recap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Tranzyme Pharma (NASDAQ:TZYM)  Closing price $0.52

On Friday, Tranzyme reported the successful finalization of its chemistry-based drug discovery partnership with Bristol-Myers Squibb Company (NYSE:BMY). Resulting from their research efforts, the former has transferred compounds to the latter for further development across multiple drug targets. Through the accord, Tranzyme keeps the option to further pursue chosen  collaboration targets for internal development.


More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business